Skip to main content

Table 1 Clinical characteristics of participants starting treatment with a GLP-1RA or a SGLT-2i

From: Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Variable

GLP-1RA

(n = 9684)

SGLT-2i

(n = 12,097)

P value

Standardized mean difference

Sex (female %)

38.1

37.0

0.152

0.022

Age (years)

60.23 (11.00)

60.82 (10.92)

0.001

0.054

Diabetes duration (years)

7.42 (5.67)

7.67 (5.79)

0.012

0.044

HbA1c (mmol/mol)

67.55 (14.75)

67.20 (14.49)

0.175

0.024

BMI (kg/m2)

33.40 (6.04)

32.41 (5.90)

< 0.001

0.166

Systolic blood pressure (mmHg)

135.17 (14.70)

135.22 (15.07)

0.856

0.003

Diastolic blood pressure (mmHg)

80.46 (9.63)

80.21 (9.77)

0.122

0.026

LDL cholesterol (mmol/L)

2.56 (0.95)

2.55 (0.95)

0.461

0.014

HDL cholesterol (mmol/L)

1.13 (0.31)

1.14 (0.32)

0.009

0.051

Triglycerides (mmol/L)

2.32 (1.58)

2.29 (1.66)

0.217

0.024

eGFR (ml/min/1.73 m2)

91.32 (24.58)

92.05 (24.07)

0.087

0.030

Microalbuminuria (%)

20.7

20.6

0.869

0.003

Macroalbuminuria (%)

4.5

4.1

0.250

0.023

Smoker (%)

15.1

15.5

0.551

0.011

History of MACE (%)

15.8

17.0

0.043

0.032

Heart failure (%)

3.5

3.8

0.353

0.014

Metformin treatment (%)

87.3

86.6

0.175

0.021

Sulfonylurea treatment (%)

29.3

29.0

0.610

0.008

Alpha-glucosidase inhibitor treatment(%)

0.4

0.4

0.412

0.012

Meglitinide treatment (%)

5.2

5.1

0.859

0.003

Thiazolidinedione treatment (%)

1.6

1.7

0.967

0.001

Antihypertensive medication (%)

73.9

73.9

0.986

0.001

RAS blocker (%)

65.7

65.7

0.979

< 0.001

Lipid-lowering medication (%)

65.0

65.3

0.705

0.006

  1. Propensity score adjusted analysis using inverse probability of treatment weighting estimating the average treatment effect for everyone. Means with standard deviations. Numbers and proportions (%)
  2. MACE major adverse cardiovascular events